Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial (2018)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1001/jamaoncol.2018.0060
- Subjects: NEOPLASIAS MAMÁRIAS; ANTINEOPLÁSICOS; RECEPTORES HORMONAIS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Jama oncology
- ISSN: 2374-2437
- Volume/Número/Paginação/Ano: v. 4, n. 7, p. 977-984, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ROYCE, Melanie e HEGG, Roberto. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, v. 4, n. 7, p. 977-984, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.0060. Acesso em: 24 jan. 2026. -
APA
Royce, M., & Hegg, R. (2018). Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, 4( 7), 977-984. doi:10.1001/jamaoncol.2018.0060 -
NLM
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060 -
Vancouver
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060 - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
Informações sobre o DOI: 10.1001/jamaoncol.2018.0060 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
